arrow
F

Fumikata Hara

aichi cancer center
H指数:20
被引数:1,397

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017

更正:原发灶与转移灶在药物疗效和预后方面的差异——一项对de novo IV期乳腺癌III期临床试验JCOG1017的探索性分析

2026-05-290
OAAI
Health-related quality of life with pertuzumab retreatment: Secondary analysis of the PRECIOUS trial

接受帕妥珠单抗再治疗患者的生活质量:PRECIOUS试验的二次分析

Breast
IF7.9
2026-05-230
OAAI
Primary tumour resection reduces the risk of major local morbidity in de novo stage IV breast cancer: secondary data analysis from the JCOG1017 randomized controlled trial

原发肿瘤切除可降低新诊断IV期乳腺癌的主要局部并发症风险:来自JCOG1017随机对照试验的二次数据分析

bjs
IF0
2026-05-010
PRE
Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017

原发性与转移部位在de novo IV期乳腺癌中药物疗效和预后的差异:一项JCOG1017 III期试验的探索性分析

2026-04-160
OAAI
HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy

HER2DX在HER2阳性早期乳腺癌老年患者中的应用:来自RESPECT试验中曲妥珠单抗±化疗的扩展随访研究

2025-11-040
OAAI
A multi-institutional dummy run on segmentation variability and plan quality of stereotactic body radiotherapy for oligometastatic disease

多机构模拟运行评估寡转移性疾病立体定向体部放射治疗的分割变异性和计划质量

2025-11-010
OAAI
Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial

转移性乳腺癌原发肿瘤切除加全身治疗与单纯全身治疗的比较 (JCOG1017,prim-bc): 一项随机临床试验

2025-07-040
OAAI
Japanese translation of the Functional Assessment of Cancer Therapy-Breast+4 (FACT-B+4) following international guidelines: a verification of linguistic validity

根据国际指南进行的癌症治疗功能评估量表-乳腺癌+4(FACT-B+4)的日语翻译:语言有效性的验证

2025-05-080
OA
Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study

新辅助帕博利珠单抗联合化疗治疗早期三阴性和雌激素受体低下的HER2-negative乳腺癌的疗效和可行性: 一项日本单机构真实世界研究

2024-12-070
PRE
Comparison of proportions and prognostic impact of pathological complete response between evaluations of representative specimen and total specimen in primary breast cancer after neoadjuvant chemoradiotherapy: an ancillary study of JCOG0306
2024-06-270
OAAI
Pilot trial of an electronic patient-reported outcome monitoring system in patients with metastatic breast cancer undergoing chemotherapy

接受化疗的转移性乳腺癌患者的电子患者报告结局监测系统的试点试验

2024-01-045
OA
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition
2023-10-0721
OAAI
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
2023-09-094
OAAI
Mitigation of paclitaxel-induced peripheral neuropathy in breast cancer patients using limb-cooling apparatus: a study protocol for a randomized controlled trial
2023-07-070
OAAI